ALE.P03 / Alentis Therap - LARVOL DELTA

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: Alentis Therapeutics AG

Monotherapy • New P1/2 trial • Biliary Cancer • Cervical Cancer • Cervical Squamous Cell Carcinoma • Cholangiocarcinoma • Colorectal Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer

Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates (ADCs) for solid tumours (PRNewswire) - "This financing will enable Alentis to begin Phase 1/2 trials for two first-in-class ADCs: ALE.P02, which targets advanced or metastatic CLDN1+ squamous solid tumours with a tubulin inhibitor payload, and ALE.P03, which targets CLDN1+ tumours with a distinct topoisomerase I inhibitor payload. FDA clearance is already obtained for ALE.P02, with clinical trials expected to commence in Q1 2025. For ALE.P03, a first-in-human trial in patients with CLDN1+ tumours is subsequently planned to start in 2025."

Financing • New P1/2 trial • Oncology • Solid Tumor